Biomarkers of idiosyncratic drug-induced liver injury (DILI) - a systematic review

References

• Björnsson ES, Bergmann OM, Björnsson HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144(7):1419–1425.
   PubMed Web of Science ®Google Scholar
• Shen T, Liu Y, Shang J, et al. Incidence and etiology of drug-induced liver injury in Mainland China. Gastroenterology. 2019 Jun;156(8):2230–2241 e11.
   PubMed Web of Science ®Google Scholar
• Aithal GP, Watkins PB, Andrade RJ, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011 Jun;89(6):806–815.
   PubMed Web of Science ®Google Scholar
• Singhal R, Harrill AH, Menguy-Vacheron F, et al. Benign elevations in serum aminotransferases and biomarkers of hepatotoxicity in healthy volunteers treated with cholestyramine. BMC Pharmacol Toxicol. 2014 Aug 3;15(1):42.
   PubMedGoogle Scholar
• Harrill AH, Roach J, Fier I, et al. The effects of heparins on the liver: application of mechanistic serum biomarkers in a randomized study in healthy volunteers. Clin Pharmacol Ther. 2012 Aug;92(2):214–220.
   PubMed Web of Science ®Google Scholar
• Jiang F, Yan H, Liang L, et al. Incidence and risk factors of anti-tuberculosis drug induced liver injury (Dili): large cohort study involving 4652 Chinese adult tuberculosis patients. Liver Int. 2021 Jul;41(7):1565–1575.
   PubMed Web of Science ®Google Scholar
• Kullak-Ublick GA, Andrade RJ, Merz M, et al. Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut. 2017 Jun;66(6):1154–1164.
   PubMed Web of Science ®Google Scholar
• Tillmann HL, Suzuki A, Barnhart HX, et al. Tools for causality assessment in drug-induced liver disease. Curr Opin Gastroenterol. 2019 May;35(3):183–190.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. Electronic address eee, Clinical Practice Guideline Panel C, Panel m. EASL clinical practice guidelines: drug-induced liver injury. J Hepatol. 2019 Jun;70(6):1222–1261.
   PubMed Web of Science ®Google Scholar
• Temple R. Hy’s law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf. 2006 Apr;15(4):241–243.
   PubMed Web of Science ®Google Scholar
• Andrade RJ, Lucena MI, Fernández MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129(2):512–521.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology. 2015;148(7):1340–1352.e7.
   PubMed Web of Science ®Google Scholar
• FDA letter of support for drug-induced liver injury (Dili) biomarker(s). 2016 [ cited 2021 09 03]. Available from: https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/UCM517355.pdf
   Google Scholar
• Roth SE, Avigan MI, Bourdet D, et al. Next-generation dili biomarkers: prioritization of biomarkers for qualification and best practices for biospecimen collection in drug development. Clin Pharmacol Ther. 2020 Feb;107(2):333–346.
   PubMed Web of Science ®Google Scholar
• Safer and faster evidence-based translation (SAFE-T). [ cited 2021 09 03]. Available from: https://www.imi.europa.eu/projects-results/project-factsheets/safe-t
   Google Scholar
• C-Path’s predictive safety testing consortium (PSTC). [ cited 2021 09 03]. Available from: https://c-path.org/programs/pstc/
   Google Scholar
• Page MJ, McKenzie JE, and Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2020 ;372:n71 doi:https://doi.org/10.1136/bmj.n71 https://www.bmj.com/content/bmj/372/bmj.n71.full.pdf.
   Google Scholar
• Glanville J, Cikalo M, Crawford F, et al. Handsearching did not yield additional unique FDG-PET diagnostic test accuracy studies compared with electronic searches: a preliminary investigation. Res Synth Methods. 2012 Sep;3(3):202–213.
   PubMed Web of Science ®Google Scholar
• Fontana RJ, Watkins PB, Bonkovsky HL, et al. Drug-induced liver injury network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 2009;32(1):55–68.
   PubMed Web of Science ®Google Scholar
• Hayden JA, Cote P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med. 2006 Mar 21;144(6):427–437.
   PubMed Web of Science ®Google Scholar
• Whiting PF, Rutjes AW, and Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011 Oct 18;155(8):529–536 doi:https://doi.org/10.7326/0003-4819-155-8-201110180-00009.
   PubMed Web of Science ®Google Scholar
• FDA-NIH Biomarker Working Group BEST (Biomarkers, EndpointS, and other Tools) Resource. : Silver Spring (MD): Food and Drug Administration (US); 2016 https://www.ncbi.nlm.nih.gov/books/NBK326791/.
   Google Scholar
• Dragoi D, Benesic A, Pichler G, et al. Proteomics analysis of monocyte-derived hepatocyte-like cells identifies integrin beta 3 as a specific biomarker for drug-induced liver injury by diclofenac. Front Pharmacol. 2018;9:699.
   PubMed Web of Science ®Google Scholar
• Thulin P, Nordahl G, Gry M, et al. Keratin-18 and microRNA-122 complement alanine aminotransferase as novel safety biomarkers for drug-induced liver injury in two human cohorts. Liver Int. 2014 Mar;34(3):367–378.
   PubMed Web of Science ®Google Scholar
• Zhang L, Niu M, Wei AW, et al. Risk profiling using metabolomic characteristics for susceptible individuals of drug-induced liver injury caused by Polygonum multiflorum. Arch Toxicol. 2020 Jan;94(1):245–256.
   PubMed Web of Science ®Google Scholar
• Rupprechter SAE, Sloan DJ, Oosthuyzen W, et al. MicroRNA-122 and cytokeratin-18 have potential as a biomarkers of drug-induced liver injury in European and African patients on treatment for mycobacterial infection. Br J Clin Pharmacol. 2021 Jan 11;87(8):3206–3217.
   PubMed Web of Science ®Google Scholar
• Church RJ, Kullak-Ublick GA, Aubrecht J, et al. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: an international collaborative effort. Hepatology. 2019;69(2): 760–773.
   PubMed Web of Science ®Google Scholar
• Soga T, Sugimoto M, Honma M, et al. Serum metabolomics reveals gamma-glutamyl dipeptides as biomarkers for discrimination among different forms of liver disease. J Hepatol. 2011 Oct;55(4):896–905.
   PubMed Web of Science ®Google Scholar
• Huang Y, Zhao X, Zhang ZT, et al. Metabolomics profiling and diagnosis biomarkers searching for drug-induced liver injury implicated to Polygonum multiflorum: a cross-sectional cohort study. Front Med (Lausanne). 2020;7:592434.
   PubMed Web of Science ®Google Scholar
• Bell LN, Vuppalanchi R, Watkins PB, et al. Serum proteomic profiling in patients with drug-induced liver injury. Aliment Pharmacol Ther. 2012:600–612. DOI:https://doi.org/10.1111/j.1365-2036.2011.04982.x.
   Google Scholar
• Steuerwald NM, Foureau DM, Norton HJ, et al. Profiles of serum cytokines in acute drug-induced liver injury and their prognostic significance. PLoS One. 2013;8(12):e81974.
   PubMed Web of Science ®Google Scholar
• Ma Z, Wang X, Yin P, et al. Serum metabolome and targeted bile acid profiling reveals potential novel biomarkers for drug-induced liver injury. Medicine (Baltimore). 2019 Aug;98(31):e16717.
   PubMed Web of Science ®Google Scholar
• Benesic A, Rotter I, Dragoi D, et al. Development and validation of a test to identify drugs that cause idiosyncratic drug-induced liver injury. Clin Gastroenterol Hepatol. 2018 Sep;16(9):1488–1494 e5.
   PubMed Web of Science ®Google Scholar
• Peta V, Tse C, Perazzo H, et al. Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (Dili) as biomarkers of recovery. PLoS One. 2017;12(12):e0189436.
   PubMed Web of Science ®Google Scholar
• Bonkovsky HL, Barnhart HX, Foureau DM, et al. Cytokine profiles in acute liver injury-results from the US drug-induced liver injury network (DILIN) and the acute liver failure study group. PLoS One. 2018;13(10):e0206389.
   PubMed Web of Science ®Google Scholar
• Russo MW, Steuerwald N, Norton HJ, et al. Profiles of miRNAs in serum in severe acute drug induced liver injury and their prognostic significance. Liver Int. 2017 May;37(5):757–764.
   PubMed Web of Science ®Google Scholar
• Xie Z, Chen E, Ouyang X, et al. Metabolomics and cytokine analysis for identification of severe drug-induced liver injury. J Proteome Res. 2019 Jun 7;18(6):2514–2524.
   PubMed Web of Science ®Google Scholar
• Imbert-Bismut F, Messous D, Thibault V, et al. Intra-laboratory analytical variability of biochemical markers of fibrosis (fibrotest) and activity (actitest) and reference ranges in healthy blood donors. Clin Chem Lab Med. 2004 Mar;42(6):323–333.
   PubMed Web of Science ®Google Scholar
• Schmidt LE, Dalhoff K. Alpha-fetoprotein is a predictor of outcome in acetaminophen-induced liver injury. Hepatology. 2005 Jan;41(1):26–31.
   PubMed Web of Science ®Google Scholar
• Vliegenthart ADB, Berends C, Potter CMJ, et al. MicroRNA-122 can be measured in capillary blood which facilitates point-of-care testing for drug-induced liver injury. Br J Clin Pharmacol. 2017 Sep;83(9):2027–2033.
   PubMed Web of Science ®Google Scholar
• Dear JW. New biomarkers for drug-induced liver injury. Hepatology. 2018;67(6):2480–2481.
   PubMed Web of Science ®Google Scholar
• Church RJ, Watkins PB. Reply. Hepatology. 2018;67(6):2481–2482.
   PubMedGoogle Scholar
• Lei X, Chen J, Ren J, et al. Liver damage associated with Polygonum multiflorum Thunb.: a systematic review of case reports and case series. Evid Based Complement Alternat Med. 2015. 2015 01 12;2015:459749.
   PubMed Web of Science ®Google Scholar
• Rao T, Liu YT, Zeng XC, et al. The hepatotoxicity of Polygonum multiflorum: the emerging role of the immune-mediated liver injury. Acta Pharmacol Sin. 2021 Jan;42(1):27–35.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Liu SH, Wang JB, et al. [Clinical analysis of drug-induced liver injury caused by Polygonum multiflorum and its preparations]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2015 Dec;35(12):1442–1447.
   PubMedGoogle Scholar
• Antoniades CG, Berry PA, Wendon JA, et al. The importance of immune dysfunction in determining outcome in acute liver failure. J Hepatol. 2008 Nov;49(5):845–861.
   PubMed Web of Science ®Google Scholar
• M’Kada H, Perazzo H, Munteanu M, et al. Real time identification of drug-induced liver injury (Dili) through daily screening of ALT results: a prospective pilot cohort study. PLoS One. 2012;7(8):e42418.
   PubMed Web of Science ®Google Scholar
• Daly AK, Donaldson PT, and Bhatnagar P, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet. 2009 Jul;41(7):816–819.
   PubMed Web of Science ®Google Scholar
• Aithal GP. Pharmacogenetic testing in idiosyncratic drug-induced liver injury: current role in clinical practice. Liver Int. 2015 Jul;35(7):1801–1808.
   PubMed Web of Science ®Google Scholar
• Kaliyaperumal K, Grove JI, Delahay RM, et al. Pharmacogenomics of drug-induced liver injury (Dili): molecular biology to clinical applications. J Hepatol. 2018 Oct;69(4):948–957.
   PubMed Web of Science ®Google Scholar